Komori
Other Disclosures4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Discontinuation of telephone support for IR inquiries

Individual telephone support for IR inquiries will end on 30 June 2026, after which all inquiries will be handled through the inquiry form. Responses will generally be provided within 3 business days, and the company has also stated that it will not answer certain questions.

Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

IR inquiry support
Applicable field (uses covered by this announcement)

IR inquiries

Launch date30 June 2026 (scheduled; telephone support will end on that date and all inquiries will be handled through the inquiry form)
What the company reported numerically
Quantitative Effects

Responses generally provided within 3 business days

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredIR inquiry support
Launch date30 June 2026 (scheduled; telephone support will end on that date and all inquiries will be handled through the inquiry form)
Applicable areaIR inquiries
Quantitative EffectsResponses generally provided within 3 business days
Items this document does not state (14)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company determined that consolidating responses to IR inquiries into a written format that leaves a record was appropriate in order to further improve fairness and accuracy and prevent differences in responses and misunderstandings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Discontinuation of telephone support for IR inquiries | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori